<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="brief-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006923</article-id><article-id pub-id-type="pmc">PMC11860839</article-id><article-id pub-id-type="doi">10.3390/v17020168</article-id><article-id pub-id-type="publisher-id">viruses-17-00168</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rodriguez</surname><given-names>Lauren</given-names></name><xref rid="af1-viruses-17-00168" ref-type="aff">1</xref><xref rid="c1-viruses-17-00168" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Zamora</surname><given-names>J. Lizbeth Reyes</given-names></name><xref rid="af1-viruses-17-00168" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Dong</given-names></name><xref rid="af1-viruses-17-00168" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Moshiri</surname><given-names>Jasmine</given-names></name><xref rid="af1-viruses-17-00168" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Peinovich</surname><given-names>Nadine</given-names></name><xref rid="af1-viruses-17-00168" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Martinez</surname><given-names>Clarissa</given-names></name><xref rid="af1-viruses-17-00168" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Ho</surname><given-names>Pui Yan</given-names></name><xref rid="af1-viruses-17-00168" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jiani</given-names></name><xref rid="af1-viruses-17-00168" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Aeschbacher</surname><given-names>Thomas</given-names></name><xref rid="af1-viruses-17-00168" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Ross</given-names></name><xref rid="af1-viruses-17-00168" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3248-1761</contrib-id><name><surname>Pekosz</surname><given-names>Andrew</given-names></name><xref rid="af2-viruses-17-00168" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4327-1727</contrib-id><name><surname>Bilello</surname><given-names>John P.</given-names></name><xref rid="af1-viruses-17-00168" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Perry</surname><given-names>Jason K.</given-names></name><xref rid="af1-viruses-17-00168" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Hedskog</surname><given-names>Charlotte</given-names></name><xref rid="af1-viruses-17-00168" ref-type="aff">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Harty</surname><given-names>Ronald N.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-17-00168"><label>1</label>Gilead Sciences, Inc., Foster City, CA 94404, USA</aff><aff id="af2-viruses-17-00168"><label>2</label>Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA</aff><author-notes><corresp id="c1-viruses-17-00168"><label>*</label>Correspondence: <email>lauren.rodriguez14@gilead.com</email>; Tel.: +1-(650)-574-3000</corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>168</elocation-id><history><date date-type="received"><day>17</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>22</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>As new SARS-CoV-2 variants continue to emerge, it is important to evaluate the potency of antiviral drugs to support their continued use. Remdesivir (RDV; VEKLURY<sup>&#x000ae;</sup>) an approved antiviral treatment for COVID-19, and obeldesivir (ODV) are inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase Nsp12. Here we show these two compounds retain antiviral activity against the Omicron variants BA.2.86, BF.7, BQ.1, CH.1.1, EG.1.2, EG.5.1, EG.5.1.4, FL.22, HK.3, HV.1, JN.1, JN.1.7, JN.1.18, KP.2, KP.3, LB.1, XBB.1.5, XBB.1.5.72, XBB.1.16, XBB.2.3.2, XBC.1.6, and XBF when compared with reference strains. Genomic analysis identified 29 Nsp12 polymorphisms in these and previous Omicron variants. Phenotypic analysis of these polymorphisms confirmed no impact on the antiviral activity of RDV or ODV and suggests Omicron variants containing these Nsp12 polymorphisms remain susceptible to both compounds. These data support the continued use of RDV in the context of circulating SARS-CoV-2 variants and the development of ODV as an antiviral therapeutic.</p></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>Omicron variants</kwd><kwd>remdesivir</kwd><kwd>genotyping</kwd><kwd>phenotyping</kwd><kwd>Nsp12</kwd></kwd-group><funding-group><award-group><funding-source>Gilead Sciences, Inc.</funding-source></award-group><funding-statement>This study was funded by Gilead Sciences, Inc.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-17-00168"><title>1. Introduction</title><p>New variants of SARS-CoV-2 have continuously emerged since the beginning of the global COVID-19 outbreak. These variants have the potential for increased transmission, enhanced antibody evasion, and reduced effectiveness of vaccines and therapeutics [<xref rid="B1-viruses-17-00168" ref-type="bibr">1</xref>,<xref rid="B2-viruses-17-00168" ref-type="bibr">2</xref>]. The Omicron variant (Pango lineage B.1.1.529) was first reported in South Africa in November 2021 and, by the end of December 2021, had quickly overtaken Delta as the most prevalent variant in the United States [<xref rid="B3-viruses-17-00168" ref-type="bibr">3</xref>,<xref rid="B4-viruses-17-00168" ref-type="bibr">4</xref>]. Since then, Omicron variants have been the predominant circulating variants of interest (VOIs) and variants under monitoring (VUMs) worldwide [<xref rid="B5-viruses-17-00168" ref-type="bibr">5</xref>,<xref rid="B6-viruses-17-00168" ref-type="bibr">6</xref>].</p><p>There remains a need for effective therapies to treat the emerging variants of SARS-CoV-2. Remdesivir (RDV; GS-5734; VEKLURY<sup>&#x000ae;</sup>) is an intravenously administered nucleotide analog prodrug approved to treat COVID-19 in hospitalized and nonhospitalized adult and pediatric patients [<xref rid="B7-viruses-17-00168" ref-type="bibr">7</xref>]. Obeldesivir (ODV; GS-5245) is an oral prodrug of the parent nucleoside of RDV with the potential to be a simple twice-daily treatment regimen with limited drug&#x02013;drug interactions [<xref rid="B8-viruses-17-00168" ref-type="bibr">8</xref>,<xref rid="B9-viruses-17-00168" ref-type="bibr">9</xref>]. Using different metabolic pathways, RDV and ODV generate the same active nucleoside triphosphate (NTP) that acts as an inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase (Nsp12) by covalently incorporating into the primer strand, thereby terminating chain elongation or resulting in template-dependent inhibition [<xref rid="B9-viruses-17-00168" ref-type="bibr">9</xref>,<xref rid="B10-viruses-17-00168" ref-type="bibr">10</xref>,<xref rid="B11-viruses-17-00168" ref-type="bibr">11</xref>]. A defining characteristic of RDV is its efficacy against a broad range of viruses [<xref rid="B12-viruses-17-00168" ref-type="bibr">12</xref>,<xref rid="B13-viruses-17-00168" ref-type="bibr">13</xref>,<xref rid="B14-viruses-17-00168" ref-type="bibr">14</xref>,<xref rid="B15-viruses-17-00168" ref-type="bibr">15</xref>,<xref rid="B16-viruses-17-00168" ref-type="bibr">16</xref>,<xref rid="B17-viruses-17-00168" ref-type="bibr">17</xref>,<xref rid="B18-viruses-17-00168" ref-type="bibr">18</xref>,<xref rid="B19-viruses-17-00168" ref-type="bibr">19</xref>,<xref rid="B20-viruses-17-00168" ref-type="bibr">20</xref>]; ODV has shown a similar antiviral profile [<xref rid="B9-viruses-17-00168" ref-type="bibr">9</xref>,<xref rid="B12-viruses-17-00168" ref-type="bibr">12</xref>,<xref rid="B21-viruses-17-00168" ref-type="bibr">21</xref>,<xref rid="B22-viruses-17-00168" ref-type="bibr">22</xref>].</p><p>As new SARS-CoV-2 variants are detected, genomic surveillance plays an important role in monitoring emergent mutations that could confer resistance to existing therapeutics. The Omicron variant is characterized by over 30 amino acid substitutions in the spike protein, which impact the efficacy of therapeutic monoclonal antibodies [<xref rid="B23-viruses-17-00168" ref-type="bibr">23</xref>]. As an example, the Omicron variants BF.7, BQ.1, XBF, XBB.1.5, and CH.1.1 exhibited greater antibody escape compared with previously detected variants, and a variety of monoclonal antibodies failed to neutralize the Omicron variants XBB.1.16 and XBB.1.9.1 [<xref rid="B24-viruses-17-00168" ref-type="bibr">24</xref>,<xref rid="B25-viruses-17-00168" ref-type="bibr">25</xref>,<xref rid="B26-viruses-17-00168" ref-type="bibr">26</xref>,<xref rid="B27-viruses-17-00168" ref-type="bibr">27</xref>]. Vaccines were consequently updated to improve protection against these and other circulating sub-lineages [<xref rid="B28-viruses-17-00168" ref-type="bibr">28</xref>,<xref rid="B29-viruses-17-00168" ref-type="bibr">29</xref>,<xref rid="B30-viruses-17-00168" ref-type="bibr">30</xref>]. More recently, the emergence of the Omicron variant BA.2.86, which has more than 30 mutations in its spike protein relative to its ancestral variant BA.2, raised global concern [<xref rid="B31-viruses-17-00168" ref-type="bibr">31</xref>]. BA.2.86 rapidly evolved into the currently circulating JN.1 sublineage [<xref rid="B32-viruses-17-00168" ref-type="bibr">32</xref>], which includes subvariants KP.2, KP.3, and LB.1 [<xref rid="B33-viruses-17-00168" ref-type="bibr">33</xref>]. These variants have shown effective immune evasion [<xref rid="B32-viruses-17-00168" ref-type="bibr">32</xref>,<xref rid="B33-viruses-17-00168" ref-type="bibr">33</xref>,<xref rid="B34-viruses-17-00168" ref-type="bibr">34</xref>], prompting recommendations to update vaccine compositions for 2024 to 2025 to target JN.1 [<xref rid="B35-viruses-17-00168" ref-type="bibr">35</xref>]. While RDV and ODV target the conserved RNA-dependent RNA polymerase region, which has minimal genetic evolution compared with the spike protein [<xref rid="B36-viruses-17-00168" ref-type="bibr">36</xref>,<xref rid="B37-viruses-17-00168" ref-type="bibr">37</xref>], it is important to confirm their remaining potency against SARS-CoV-2 variants to support continued use in COVID-19 treatment and development. Here, we assess the antiviral activity of RDV and ODV against recent Omicron variants using clinical isolates or by introducing the variant-defining substitutions present in the replication complex into a replicon system. In addition, the antiviral activity of RDV and ODV against Nsp12 polymorphisms observed in public databases was assessed in the replicon system.</p></sec><sec id="sec2-viruses-17-00168"><title>2. Materials and Methods</title><p>To evaluate the in vitro antiviral activity of RDV and ODV against the Omicron variants BA.2.86, BF.7, BQ.1, CH.1.1, EG.1.2, EG.5.1, EG.5.1.4, FL.22, HK.3, HV.1, JN.1, XBB.1.5, XBB.1.5.72, XBB.1.16, XBB.2.3.2, XBC.1.6, and XBF, a previously described SARS-CoV-2 anti-nucleoprotein enzyme-linked immunosorbent assay (ELISA) was utilized in A549-hACE2-TMPRSS2 cells (a549-hace2tpsa; InvivoGen, San Diego, CA, USA) [<xref rid="B9-viruses-17-00168" ref-type="bibr">9</xref>,<xref rid="B38-viruses-17-00168" ref-type="bibr">38</xref>]. A total of 3 &#x000d7; 10<sup>4</sup> A549-hACE2-TMPRSS2 cells in 100 &#x000b5;L Dulbecco&#x02019;s Modified Eagle Medium (DMEM; supplemented with 10% fetal bovine serum [FBS] and 1&#x000d7; penicillin-streptomycin) were seeded into each well of a 96-well plate and incubated overnight. The following day, the medium was aspirated, and 100 &#x000b5;L of DMEM containing 2% FBS was added to each well. In triplicate, 3-fold serial dilutions of RDV (5&#x02013;0.002 &#x000b5;M) or ODV (50&#x02013;0.02 &#x000b5;M) were added to each well for a final volume of 200 &#x000b5;L/well. Immediately after compound addition, cells were infected with 1.5 &#x000d7; 10<sup>3</sup> plaque-forming units of the relevant SARS-CoV-2 variant diluted in 100 &#x000b5;L of DMEM supplemented with 2% FBS, resulting in a multiplicity of infection of 0.05. Plates were centrifuged for 1 min at 500&#x000d7; <italic toggle="yes">g</italic> and then incubated at 37 &#x000b0;C with 5% CO<sub>2</sub> for 3 days, after which the medium was aspirated and cells were fixed with 100% methanol for 10 min at room temperature (RT). The methanol was removed, and plates were air dried for 10 min at RT, followed by 1 h of incubation with 100&#x000b5;L/well of blocking buffer (phosphate-buffered saline [PBS] with 10% FBS, 5% nonfat dry milk, and 0.1% Tween 20) for 1 h at 37 &#x000b0;C. The blocking buffer was then aspirated, and 50 &#x000b5;L of a 1:10,000 dilution of rabbit anti-SARS-CoV-2 nucleocapsid antibody (MA5-36086 [4Z6T2]; Invitrogen, Waltham, MA, USA) in a blocking buffer was added and incubated for 2 h at 37 &#x000b0;C. Plates were washed 4 times with 200 &#x000b5;L/well of PBS containing 0.1% Tween 20 prior to the addition of 50 &#x000b5;L/well of horseradish peroxidase conjugated goat anti&#x02013;rabbit IgG (GtxRb-003-FHRPX; ImmunoReagents, Raleigh, NC, USA) diluted 1:4000 in a blocking buffer. Plates were again incubated for 1 h at 37 &#x000b0;C and then washed 4 times with 200 &#x000b5;L PBS with 0.1% Tween 20. A total of 100 &#x000b5;L of 3,39,5,59-tetramethylbenzidene (TMB) reagent (ENN301; Thermo Scientific, Waltham, MA, USA) was added to each well and allowed to incubate at RT until visible staining of the positive control wells&#x02014;usually 5 to 10 min. The reaction was stopped with the addition of 100 &#x000b5;L/well of TMB stop solution (5150-0021; SeraCare, Milford, MA, USA). The absorbance was then read at 450 nm using an EnVision plate reader.</p><p>The half-maximal effective concentration (EC<sub>50</sub>) values were defined as the compound concentration at which there was a 50% reduction in nucleoprotein expression (ELISA) or luciferase signal (replicons) relative to infected cells with DMSO alone (0% inhibition) and uninfected control cells (100% inhibition). RDV and ODV EC<sub>50</sub> values were calculated from curve fits using nonlinear regression (GraphPad Prism v8.1.2). EC<sub>50</sub> fold change for variants was calculated for each experiment, for comparison with the relevant WA1 reference. Fold change across all experiments was then averaged to obtain the final reported values. For each clinical isolate, experiments were performed twice with technical triplicates. The variability of the ELISA assay was estimated after repeat testing of the wildtype reference (RDV, n = 40; ODV, n = 11). The RDV EC<sub>50</sub> values for the wildtype clinical isolate ranged between 44.2 nM and 196.8 nM (mean, 112.1 nM; median, 103.4 nM; standard deviation, 35.2 nM). Based on these data, we estimated that the assay variability was 2.8-fold. The ODV EC<sub>50</sub> values for the wildtype clinical isolate ranged between 1.43 &#x000b5;M and 4.17 &#x000b5;M (mean, 2.29 &#x000b5;M; median, 2.11 &#x000b5;M; standard deviation, 0.75). Based on these data, we estimated that the assay variability was 2.9-fold. The variability of the subgenomic replicon assay was also estimated after repeated testing of the wildtype reference (RDV, n = 44; ODV, n = 36). The RDV EC<sub>50</sub> values for the wildtype replicon ranged between 3.7 nM and 30.8 nM (mean, 11.3 nM; median, 10.1 nM; standard deviation, 4.6 nM); the estimated assay variability was 2.5-fold. The ODV EC<sub>50</sub> values for the wildtype replicon ranged from 0.38 &#x000b5;M to 0.97 &#x000b5;M (mean, 0.62 &#x000b5;M; median, 0.61 &#x000b5;M; standard deviation, 0.14 &#x000b5;M); the estimated assay variability was 2.3-fold. Thus, any variant with fold change values below the respective threshold for RDV or ODV is within the variability of the assay.</p><p>For Omicron variants JN.1.7, JN.1.18, KP.2, KP.3, and LB.1, clinical isolates were not available; thus, a noninfectious SARS-CoV-2 replicon system (four DNA fragments isolated from SARS-CoV-2 SH01, SARS-CoV-2/human/CHN/SH01/2020, GenBank MT121215) was used to assess RDV and ODV antiviral activity. The established replicon method has been previously described [<xref rid="B39-viruses-17-00168" ref-type="bibr">39</xref>] and used for phenotypic analysis of SARS-CoV-2 site-directed mutants of the replication complex components [<xref rid="B40-viruses-17-00168" ref-type="bibr">40</xref>,<xref rid="B41-viruses-17-00168" ref-type="bibr">41</xref>]. Briefly, the variant-defining substitutions identified in the replication complex genes (Nsp8 to Nsp14) were introduced into the luciferase-expressing replicon, the replicon was transfected into Huh7-1CN cells by electroporation, and cells were treated with 4-fold serial dilutions of RDV (8 dilutions total; 10 &#x000b5;M&#x02013;0.6 nM) or ODV (8 dilutions total; 200 &#x000b5;M&#x02013;12 nM). After 48 h, cell supernatants were collected, and luciferase signal was measured to determine EC<sub>50</sub> values of each compound by curve fits using non-linear regression (GraphPad Prism v8.1.2). Two experiments were performed with technical triplicates.</p><p>To evaluate the prevalence of Nsp12 polymorphisms (&#x02265;1% of sequences) observed in Omicron variants of concern, VOIs, or VUMs, SARS-CoV-2 sequences from the Global Initiative on Sharing Avian Influenza Data EpiCoV database were evaluated. To assess the impact of Nsp12 polymorphisms on the antiviral activity of RDV and ODV, site-directed mutants bearing the identified Nsp12 polymorphisms were evaluated using the same replicon system described above.</p><p>Structural analysis of the identified polymorphisms was conducted on a composite model of cryo-electron microscopy structures of the replication-transcription complex retrieved from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (ID#: 6XEZ and 7UO4) [<xref rid="B42-viruses-17-00168" ref-type="bibr">42</xref>,<xref rid="B43-viruses-17-00168" ref-type="bibr">43</xref>].</p></sec><sec sec-type="results" id="sec3-viruses-17-00168"><title>3. Results</title><sec id="sec3dot1-viruses-17-00168"><title>3.1. Antiviral Activity of RDV and ODV Against Clinical Isolates of Omicron Variants</title><p>Mean RDV EC<sub>50</sub> values for all tested Omicron variants (BA.2.86, BF.7, BQ.1, CH.1.1, EG.1.2, EG.5.1, EG.5.1.4, FL.22, HK.3, HV.1, JN.1, XBB.1.5, XBB.1.5.72, XBB.1.16, XBB.2.3.2, XBC.1.6, and XBF) ranged from 21.8 nM (XBB.2.3.2) to 155 nM (CH.1.1), with a fold change range of 0.28 (JN.1) to 1.25 (BF.7) compared with the WA1 reference strain (<xref rid="viruses-17-00168-t001" ref-type="table">Table 1</xref>, <xref rid="viruses-17-00168-f001" ref-type="fig">Figure 1</xref>). Mean ODV EC<sub>50</sub> values ranged from 438 nM (BA.2.86) to 3193 nM (HV.1), with a fold change range of 0.23 (BA.2.86) to 1.24 (BF.7) compared with the WA1 reference strain (<xref rid="viruses-17-00168-t001" ref-type="table">Table 1</xref>). All EC<sub>50</sub> fold change values were within the variability of the assay. Overall, these results demonstrated that the tested Omicron variants remained as susceptible to RDV and ODV as the ancestral WA1 isolate.</p></sec><sec id="sec3dot2-viruses-17-00168"><title>3.2. Antiviral Activity of RDV and ODV Against Omicron Variants in the Replicon System</title><p>For Omicron variants JN.1.7, JN.1.18, KP.2, KP.3, and LB.1, clinical isolates were not available; thus, the variant-defining substitutions observed in the replication complex of these variants were introduced into a replicon by site-directed mutagenesis to assess RDV and ODV antiviral activity. When tested in replicons bearing the substitutions in the replication complex genes, mean EC<sub>50</sub> values for RDV and ODV against these variants were 12.6 nM and 465 nM, respectively (<xref rid="viruses-17-00168-t001" ref-type="table">Table 1</xref>). The EC<sub>50</sub> fold changes were 1.14 for RDV and 1.05 for ODV compared with the wildtype reference replicon. All EC<sub>50</sub> fold change values were within the variability of the assay, demonstrating no change in susceptibility.</p></sec><sec id="sec3dot3-viruses-17-00168"><title>3.3. Characterization of Nsp12 Polymorphisms Observed in Omicron Variants</title><p>Analysis of more than 2 million Omicron variant sequences revealed 29 polymorphisms in Nsp12 compared with the Wuhan reference (Wuhan-Hu-1 viral isolate; NC_045512). The Nsp12-defining amino acid substitutions (&#x02265;75% of sequences) included P323L, which was observed in all Omicron variants; Y273H, which was observed in BQ.1; G671S, which was observed in XBB.1.5, CH.1.1, and XBF; D63N, which was observed in HK.3; and G823insD, which was observed in XBC.1.6 (<xref rid="viruses-17-00168-t001" ref-type="table">Table 1</xref>). Less prevalent polymorphisms were observed with frequencies ranging from 1.0% to 15.9% (T26I, D40G, T85I, G108D, D155G, I171V, Y175H, I223M, T225I, L247F, T248I, V257F, D258N, Y289H, D303N, T394M, P461S, V476A, N507I, A529V, M666I, F694Y, T803I, V848I; <xref rid="viruses-17-00168-t001" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3dot4-viruses-17-00168"><title>3.4. Impact of Nsp12 Polymorphisms on RDV and ODV Antiviral Activity in the Replicon System</title><p>Each substitution was introduced into the replicon system by site-directed mutagenesis, and mean RDV EC<sub>50</sub> values ranged from 3.88 nM (T85I) to 18.0 nM (P461S), with fold changes ranging from 0.52 (L247F) to 1.60 (P461S, G671S) compared with the SH01 wildtype reference replicon (<xref rid="viruses-17-00168-t001" ref-type="table">Table 1</xref>). Mean ODV EC<sub>50</sub> values ranged from 212 nM (D155G) to 1322 nM (G671S), with fold changes ranging from 0.47 (D155G, V257F) to 1.76 (G671S) compared with the reference replicon. Altogether, this phenotypic analysis of Nsp12 polymorphisms showed no change in RDV or ODV susceptibility.</p></sec><sec id="sec3dot5-viruses-17-00168"><title>3.5. Structural Analysis of Identified Nsp12 Polymorphisms</title><p>None of the polymorphisms showed direct interaction with the incoming active NTP substrate or the viral RNA, except N507I, which interacts with the 5&#x02032; template overhang (<xref rid="viruses-17-00168-f002" ref-type="fig">Figure 2</xref>). Despite this interaction, phenotyping of the N507I replicon showed no reduction in susceptibility to RDV or ODV (<xref rid="viruses-17-00168-t001" ref-type="table">Table 1</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-17-00168"><title>4. Discussion</title><p>Since May 2024, the United States has observed a rise in COVID-19 activity, including increases in the rates of test positivity, hospitalizations, and deaths [<xref rid="B5-viruses-17-00168" ref-type="bibr">5</xref>]. This resurgence is largely driven by the latest SARS-CoV-2 Omicron variants, including KP.2 and KP.3 [<xref rid="B5-viruses-17-00168" ref-type="bibr">5</xref>], with growing concern that even more severe variants may be forthcoming. Among the associated public health challenges, the ongoing emergence of new variants poses a potential risk for changes in susceptibility to antiviral drugs. Therefore, it is crucial to continually test the susceptibility of new variants to widely used antiviral therapies, such as RDV, to ensure persistent treatment efficacy.</p><p>In this analysis, the in vitro antiviral activity of RDV and ODV, an oral prodrug of the parent nucleoside of RDV, against recent SARS-CoV-2 Omicron subvariants was assessed. RDV and ODV maintained activity against all tested Omicron variants, with potencies that were comparable with those observed when tested against the ancestral reference. Phenotyping of the 29 identified Nsp12 polymorphisms similarly showed no change in RDV or ODV antiviral activity relative to the SH01 reference strain.</p><p>These results are consistent with previous analyses wherein multiple Omicron variants that were distinct from those analyzed herein and earlier VOIs and VUMs remained susceptible to both compounds [<xref rid="B9-viruses-17-00168" ref-type="bibr">9</xref>,<xref rid="B38-viruses-17-00168" ref-type="bibr">38</xref>]. Together, these findings support continued use of RDV for the treatment of COVID-19 in the context of Omicron variants.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was funded by Gilead Sciences, Inc. Medical writing and editorial support were provided by Bethany Reinecke of Lumanity Communications, Inc. (Yardley, PA, USA), and were funded by Gilead Sciences, Inc.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, L.R. and C.H.; data curation, L.R., J.L.R.Z., D.H., J.M., N.P., C.M., P.Y.H., J.L., T.A. and A.P.; formal analysis, L.R., J.L.R.Z., J.M., J.L. and C.H.; funding acquisition, C.H.; investigation, L.R., J.L.R.Z. and J.L.; methodology, L.R., J.L.R.Z., D.H., J.L. and C.H.; project administration, C.H.; resources, L.R., J.L.R.Z., J.L., A.P. and C.H.; supervision, C.H.; validation, L.R., J.L.R.Z., J.L. and C.H.; visualization, L.R.; writing&#x02014;original draft, L.R; writing&#x02014;review and editing, L.R., J.L.R.Z., D.H., J.M., N.P., C.M., P.Y.H., J.L., T.A., R.M., A.P., J.P.B., J.K.P. and C.H. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors upon request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>L.R., J.L.R.Z., D.H., J.M., N.P., C.M., P.Y.H., J.L., T.A., R.M., J.P.B., J.K.P., and C.H. are employees of Gilead Sciences, Inc. A.P. declares no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-17-00168"><label>1.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Updated Working Definitions and Primary Actions for SARS-CoV-2 Variants</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/publications/m/item/updated-working-definitions-and-primary-actions-for--sars-cov-2-variants" ext-link-type="uri">https://www.who.int/publications/m/item/updated-working-definitions-and-primary-actions-for--sars-cov-2-variants</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-07-07">(accessed on 7 July 2023)</date-in-citation></element-citation></ref><ref id="B2-viruses-17-00168"><label>2.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Centers for Disease Control and Prevention</collab>
</person-group><article-title>SARS-CoV-2 Variant Classifications and Definitions</article-title><comment>Available online: <ext-link xlink:href="https://stacks.cdc.gov/view/cdc/10581" ext-link-type="uri">https://stacks.cdc.gov/view/cdc/10581</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-07-30">(accessed on 30 July 2024)</date-in-citation></element-citation></ref><ref id="B3-viruses-17-00168"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>CDC COVID-19 Response Team</collab>
</person-group><article-title>SARS-CoV-2 B.1.1.529 (Omicron) variant&#x02014;United States, December 1&#x02013;8, 2021</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2021</year><volume>70</volume><fpage>1731</fpage><lpage>1734</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7050e1</pub-id><pub-id pub-id-type="pmid">34914670</pub-id>
</element-citation></ref><ref id="B4-viruses-17-00168"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adjei</surname><given-names>S.</given-names></name>
<name><surname>Hong</surname><given-names>K.</given-names></name>
<name><surname>Molinari</surname><given-names>N.M.</given-names></name>
<name><surname>Bull-Otterson</surname><given-names>L.</given-names></name>
<name><surname>Ajani</surname><given-names>U.A.</given-names></name>
<name><surname>Gundlapalli</surname><given-names>A.V.</given-names></name>
<name><surname>Harris</surname><given-names>A.M.</given-names></name>
<name><surname>Hsu</surname><given-names>J.</given-names></name>
<name><surname>Kadri</surname><given-names>S.S.</given-names></name>
<name><surname>Starnes</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Mortality risk among patients hospitalized primarily for COVID-19 during the Omicron and Delta variant pandemic periods&#x02014;United States, April 2020-June 2022</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2022</year><volume>71</volume><fpage>1182</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7137a4</pub-id><pub-id pub-id-type="pmid">36107788</pub-id>
</element-citation></ref><ref id="B5-viruses-17-00168"><label>5.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Centers for Disease Control and Prevention</collab>
</person-group><article-title>COVID Data Tracker</article-title><comment>Available online: <ext-link xlink:href="https://covid.cdc.gov/covid-data-tracker/" ext-link-type="uri">https://covid.cdc.gov/covid-data-tracker/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-11-20">(accessed on 20 November 2023)</date-in-citation></element-citation></ref><ref id="B6-viruses-17-00168"><label>6.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Tracking SARS-CoV-2 variants</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/" ext-link-type="uri">https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-07-30">(accessed on 30 July 2024)</date-in-citation></element-citation></ref><ref id="B7-viruses-17-00168"><label>7.</label><element-citation publication-type="book"><source>VEKLURY<sup>&#x000ae;</sup> (Remdesivir) [Prescribing Information]</source><publisher-name>Gilead Sciences, Inc.</publisher-name><publisher-loc>Foster City, CA, USA</publisher-loc><year>2022</year></element-citation></ref><ref id="B8-viruses-17-00168"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amini</surname><given-names>E.</given-names></name>
<name><surname>Shelton</surname><given-names>M.</given-names></name>
<name><surname>Raut</surname><given-names>A.</given-names></name>
<name><surname>Kwan</surname><given-names>A.</given-names></name>
<name><surname>Xiao</surname><given-names>D.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Madera</surname><given-names>S.</given-names></name>
<name><surname>Llewellyn</surname><given-names>J.</given-names></name>
<name><surname>Winter</surname><given-names>H.</given-names></name>
<name><surname>Humeniuk</surname><given-names>R.</given-names></name>
</person-group><article-title>505. Drug-drug interaction profiling of obeldesivir, a promising oral treatment for COVID-19</article-title><source>Open Forum Infect. Dis.</source><year>2023</year><volume>10</volume><fpage>ofad500.574</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofad500.574</pub-id></element-citation></ref><ref id="B9-viruses-17-00168"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mackman</surname><given-names>R.L.</given-names></name>
<name><surname>Kalla</surname><given-names>R.V.</given-names></name>
<name><surname>Babusis</surname><given-names>D.</given-names></name>
<name><surname>Pitts</surname><given-names>J.</given-names></name>
<name><surname>Barrett</surname><given-names>K.T.</given-names></name>
<name><surname>Chun</surname><given-names>K.</given-names></name>
<name><surname>Du Pont</surname><given-names>V.</given-names></name>
<name><surname>Rodriguez</surname><given-names>L.</given-names></name>
<name><surname>Moshiri</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Discovery of GS-5245 (obeldesivir), an oral prodrug of nucleoside GS-441524 that exhibits antiviral efficacy in SARS-CoV-2-infected African green monkeys</article-title><source>J. Med. Chem.</source><year>2023</year><volume>66</volume><fpage>11701</fpage><lpage>11717</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.3c00750</pub-id><pub-id pub-id-type="pmid">37596939</pub-id>
</element-citation></ref><ref id="B10-viruses-17-00168"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yin</surname><given-names>W.</given-names></name>
<name><surname>Mao</surname><given-names>C.</given-names></name>
<name><surname>Luan</surname><given-names>X.</given-names></name>
<name><surname>Shen</surname><given-names>D.D.</given-names></name>
<name><surname>Shen</surname><given-names>Q.</given-names></name>
<name><surname>Su</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>F.</given-names></name>
<name><surname>Zhao</surname><given-names>W.</given-names></name>
<name><surname>Gao</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir</article-title><source>Science</source><year>2020</year><volume>368</volume><fpage>1499</fpage><lpage>1504</lpage><pub-id pub-id-type="doi">10.1126/science.abc1560</pub-id><pub-id pub-id-type="pmid">32358203</pub-id>
</element-citation></ref><ref id="B11-viruses-17-00168"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tchesnokov</surname><given-names>E.P.</given-names></name>
<name><surname>Gordon</surname><given-names>C.J.</given-names></name>
<name><surname>Woolner</surname><given-names>E.</given-names></name>
<name><surname>Kocinkova</surname><given-names>D.</given-names></name>
<name><surname>Perry</surname><given-names>J.K.</given-names></name>
<name><surname>Feng</surname><given-names>J.Y.</given-names></name>
<name><surname>Porter</surname><given-names>D.P.</given-names></name>
<name><surname>Gotte</surname><given-names>M.</given-names></name>
</person-group><article-title>Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action</article-title><source>J. Biol. Chem.</source><year>2020</year><volume>295</volume><fpage>16156</fpage><lpage>16165</lpage><pub-id pub-id-type="doi">10.1074/jbc.AC120.015720</pub-id><pub-id pub-id-type="pmid">32967965</pub-id>
</element-citation></ref><ref id="B12-viruses-17-00168"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lo</surname><given-names>M.K.</given-names></name>
<name><surname>Jordan</surname><given-names>R.</given-names></name>
<name><surname>Arvey</surname><given-names>A.</given-names></name>
<name><surname>Sudhamsu</surname><given-names>J.</given-names></name>
<name><surname>Shrivastava-Ranjan</surname><given-names>P.</given-names></name>
<name><surname>Hotard</surname><given-names>A.L.</given-names></name>
<name><surname>Flint</surname><given-names>M.</given-names></name>
<name><surname>McMullan</surname><given-names>L.K.</given-names></name>
<name><surname>Siegel</surname><given-names>D.</given-names></name>
<name><surname>Clarke</surname><given-names>M.O.</given-names></name>
<etal/>
</person-group><article-title>GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>43395</elocation-id><pub-id pub-id-type="doi">10.1038/srep43395</pub-id><pub-id pub-id-type="pmid">28262699</pub-id>
</element-citation></ref><ref id="B13-viruses-17-00168"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sheahan</surname><given-names>T.P.</given-names></name>
<name><surname>Sims</surname><given-names>A.C.</given-names></name>
<name><surname>Graham</surname><given-names>R.L.</given-names></name>
<name><surname>Menachery</surname><given-names>V.D.</given-names></name>
<name><surname>Gralinski</surname><given-names>L.E.</given-names></name>
<name><surname>Case</surname><given-names>J.B.</given-names></name>
<name><surname>Leist</surname><given-names>S.R.</given-names></name>
<name><surname>Pyrc</surname><given-names>K.</given-names></name>
<name><surname>Feng</surname><given-names>J.Y.</given-names></name>
<name><surname>Trantcheva</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses</article-title><source>Sci. Transl. Med.</source><year>2017</year><volume>9</volume><fpage>eaal3653</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aal3653</pub-id><pub-id pub-id-type="pmid">28659436</pub-id>
</element-citation></ref><ref id="B14-viruses-17-00168"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pruijssers</surname><given-names>A.J.</given-names></name>
<name><surname>George</surname><given-names>A.S.</given-names></name>
<name><surname>Schafer</surname><given-names>A.</given-names></name>
<name><surname>Leist</surname><given-names>S.R.</given-names></name>
<name><surname>Gralinksi</surname><given-names>L.E.</given-names></name>
<name><surname>Dinnon</surname><given-names>K.H.</given-names><suffix>III</suffix></name>
<name><surname>Yount</surname><given-names>B.L.</given-names></name>
<name><surname>Agostini</surname><given-names>M.L.</given-names></name>
<name><surname>Stevens</surname><given-names>L.J.</given-names></name>
<name><surname>Chappell</surname><given-names>J.D.</given-names></name>
<etal/>
</person-group><article-title>Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice</article-title><source>Cell Rep.</source><year>2020</year><volume>32</volume><fpage>107940</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2020.107940</pub-id><pub-id pub-id-type="pmid">32668216</pub-id>
</element-citation></ref><ref id="B15-viruses-17-00168"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agostini</surname><given-names>M.L.</given-names></name>
<name><surname>Andres</surname><given-names>E.L.</given-names></name>
<name><surname>Sims</surname><given-names>A.C.</given-names></name>
<name><surname>Graham</surname><given-names>R.L.</given-names></name>
<name><surname>Sheahan</surname><given-names>T.P.</given-names></name>
<name><surname>Lu</surname><given-names>X.</given-names></name>
<name><surname>Smith</surname><given-names>E.C.</given-names></name>
<name><surname>Case</surname><given-names>J.B.</given-names></name>
<name><surname>Feng</surname><given-names>J.Y.</given-names></name>
<name><surname>Jordan</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease</article-title><source>mBio</source><year>2018</year><volume>9</volume><fpage>e00221-18</fpage><pub-id pub-id-type="doi">10.1128/mBio.00221-18</pub-id><pub-id pub-id-type="pmid">29511076</pub-id>
</element-citation></ref><ref id="B16-viruses-17-00168"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mackman</surname><given-names>R.L.</given-names></name>
<name><surname>Hui</surname><given-names>H.C.</given-names></name>
<name><surname>Perron</surname><given-names>M.</given-names></name>
<name><surname>Murakami</surname><given-names>E.</given-names></name>
<name><surname>Palmiotti</surname><given-names>C.</given-names></name>
<name><surname>Lee</surname><given-names>G.</given-names></name>
<name><surname>Stray</surname><given-names>K.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Goyal</surname><given-names>B.</given-names></name>
<name><surname>Chun</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Prodrugs of a 1&#x02032;-CN-4-Aza-7,9-dideazaadenosine C-nucleoside leading to the discovery of remdesivir (GS-5734) as a potent inhibitor of respiratory syncytial virus with efficacy in the African green monkey model of RSV</article-title><source>J. Med. Chem.</source><year>2021</year><volume>64</volume><fpage>5001</fpage><lpage>5017</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c00071</pub-id><pub-id pub-id-type="pmid">33835812</pub-id>
</element-citation></ref><ref id="B17-viruses-17-00168"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Warren</surname><given-names>T.K.</given-names></name>
<name><surname>Jordan</surname><given-names>R.</given-names></name>
<name><surname>Lo</surname><given-names>M.K.</given-names></name>
<name><surname>Ray</surname><given-names>A.S.</given-names></name>
<name><surname>Mackman</surname><given-names>R.L.</given-names></name>
<name><surname>Soloveva</surname><given-names>V.</given-names></name>
<name><surname>Siegel</surname><given-names>D.</given-names></name>
<name><surname>Perron</surname><given-names>M.</given-names></name>
<name><surname>Bannister</surname><given-names>R.</given-names></name>
<name><surname>Hui</surname><given-names>H.C.</given-names></name>
<etal/>
</person-group><article-title>Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys</article-title><source>Nature</source><year>2016</year><volume>531</volume><fpage>381</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1038/nature17180</pub-id><pub-id pub-id-type="pmid">26934220</pub-id>
</element-citation></ref><ref id="B18-viruses-17-00168"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Radoshitzky</surname><given-names>S.R.</given-names></name>
<name><surname>Iversen</surname><given-names>P.</given-names></name>
<name><surname>Lu</surname><given-names>X.</given-names></name>
<name><surname>Zou</surname><given-names>J.</given-names></name>
<name><surname>Kaptein</surname><given-names>S.J.F.</given-names></name>
<name><surname>Stuthman</surname><given-names>K.S.</given-names></name>
<name><surname>Van Tongeren</surname><given-names>S.A.</given-names></name>
<name><surname>Steffens</surname><given-names>J.</given-names></name>
<name><surname>Gong</surname><given-names>R.</given-names></name>
<name><surname>Truong</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Expanded profiling of remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>3131</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-29517-9</pub-id><pub-id pub-id-type="pmid">36823196</pub-id>
</element-citation></ref><ref id="B19-viruses-17-00168"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pitts</surname><given-names>J.</given-names></name>
<name><surname>Babusis</surname><given-names>D.</given-names></name>
<name><surname>Vermillion</surname><given-names>M.S.</given-names></name>
<name><surname>Subramanian</surname><given-names>R.</given-names></name>
<name><surname>Barrett</surname><given-names>K.</given-names></name>
<name><surname>Lye</surname><given-names>D.</given-names></name>
<name><surname>Ma</surname><given-names>B.</given-names></name>
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Riola</surname><given-names>N.</given-names></name>
<name><surname>Xie</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection</article-title><source>Antivir. Res.</source><year>2022</year><volume>203</volume><fpage>105329</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2022.105329</pub-id><pub-id pub-id-type="pmid">35525335</pub-id>
</element-citation></ref><ref id="B20-viruses-17-00168"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>X.</given-names></name>
<name><surname>Muruato</surname><given-names>A.E.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Lokugamage</surname><given-names>K.G.</given-names></name>
<name><surname>Fontes-Garfias</surname><given-names>C.R.</given-names></name>
<name><surname>Zou</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Ren</surname><given-names>P.</given-names></name>
<name><surname>Balakrishnan</surname><given-names>M.</given-names></name>
<name><surname>Cihlar</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>5214</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-19055-7</pub-id><pub-id pub-id-type="pmid">33060595</pub-id>
</element-citation></ref><ref id="B21-viruses-17-00168"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cross</surname><given-names>R.W.</given-names></name>
<name><surname>Woolsey</surname><given-names>C.</given-names></name>
<name><surname>Chu</surname><given-names>V.C.</given-names></name>
<name><surname>Babusis</surname><given-names>D.</given-names></name>
<name><surname>Bannister</surname><given-names>R.</given-names></name>
<name><surname>Vermillion</surname><given-names>M.S.</given-names></name>
<name><surname>Geleziunas</surname><given-names>R.</given-names></name>
<name><surname>Barrett</surname><given-names>K.T.</given-names></name>
<name><surname>Bunyan</surname><given-names>E.</given-names></name>
<name><surname>Nguyen</surname><given-names>A.Q.</given-names></name>
<etal/>
</person-group><article-title>Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus</article-title><source>Science</source><year>2024</year><volume>383</volume><fpage>eadk6176</fpage><pub-id pub-id-type="doi">10.1126/science.adk6176</pub-id><pub-id pub-id-type="pmid">38484056</pub-id>
</element-citation></ref><ref id="B22-viruses-17-00168"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martinez</surname><given-names>D.R.</given-names></name>
<name><surname>Moreira</surname><given-names>F.R.</given-names></name>
<name><surname>Catanzaro</surname><given-names>N.J.</given-names></name>
<name><surname>Diefenbacher</surname><given-names>M.V.</given-names></name>
<name><surname>Zweigart</surname><given-names>M.R.</given-names></name>
<name><surname>Gully</surname><given-names>K.L.</given-names></name>
<name><surname>De la Cruz</surname><given-names>G.</given-names></name>
<name><surname>Brown</surname><given-names>A.J.</given-names></name>
<name><surname>Adams</surname><given-names>L.E.</given-names></name>
<name><surname>Yount</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses</article-title><source>Sci. Transl. Med.</source><year>2024</year><volume>16</volume><fpage>eadj4504</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.adj4504</pub-id><pub-id pub-id-type="pmid">38776389</pub-id>
</element-citation></ref><ref id="B23-viruses-17-00168"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>VanBlargan</surname><given-names>L.A.</given-names></name>
<name><surname>Errico</surname><given-names>J.M.</given-names></name>
<name><surname>Halfmann</surname><given-names>P.J.</given-names></name>
<name><surname>Zost</surname><given-names>S.J.</given-names></name>
<name><surname>Crowe</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name>
<name><surname>Purcell</surname><given-names>L.A.</given-names></name>
<name><surname>Kawaoka</surname><given-names>Y.</given-names></name>
<name><surname>Corti</surname><given-names>D.</given-names></name>
<name><surname>Fremont</surname><given-names>D.H.</given-names></name>
<name><surname>Diamond</surname><given-names>M.S.</given-names></name>
</person-group><article-title>An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>490</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01678-y</pub-id><pub-id pub-id-type="pmid">35046573</pub-id>
</element-citation></ref><ref id="B24-viruses-17-00168"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akerman</surname><given-names>A.</given-names></name>
<name><surname>Milogiannakis</surname><given-names>V.</given-names></name>
<name><surname>Jean</surname><given-names>T.</given-names></name>
<name><surname>Esneau</surname><given-names>C.</given-names></name>
<name><surname>Silva</surname><given-names>M.R.</given-names></name>
<name><surname>Ison</surname><given-names>T.</given-names></name>
<name><surname>Fichter</surname><given-names>C.</given-names></name>
<name><surname>Lopez</surname><given-names>J.A.</given-names></name>
<name><surname>Chandra</surname><given-names>D.</given-names></name>
<name><surname>Naing</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level</article-title><source>EBioMedicine</source><year>2023</year><volume>90</volume><elocation-id>104545</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2023.104545</pub-id><pub-id pub-id-type="pmid">37002990</pub-id>
</element-citation></ref><ref id="B25-viruses-17-00168"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pochtovyi</surname><given-names>A.A.</given-names></name>
<name><surname>Kustova</surname><given-names>D.D.</given-names></name>
<name><surname>Siniavin</surname><given-names>A.E.</given-names></name>
<name><surname>Dolzhikova</surname><given-names>I.V.</given-names></name>
<name><surname>Shidlovskaya</surname><given-names>E.V.</given-names></name>
<name><surname>Shpakova</surname><given-names>O.G.</given-names></name>
<name><surname>Vasilchenko</surname><given-names>L.A.</given-names></name>
<name><surname>Glavatskaya</surname><given-names>A.A.</given-names></name>
<name><surname>Kuznetsova</surname><given-names>N.A.</given-names></name>
<name><surname>Iliukhina</surname><given-names>A.A.</given-names></name>
<etal/>
</person-group><article-title>In vitro efficacy of antivirals and monoclonal antibodies against SARS-CoV-2 Omicron lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1533</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11101533</pub-id><pub-id pub-id-type="pmid">37896937</pub-id>
</element-citation></ref><ref id="B26-viruses-17-00168"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qu</surname><given-names>P.</given-names></name>
<name><surname>Faraone</surname><given-names>J.N.</given-names></name>
<name><surname>Evans</surname><given-names>J.P.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.M.</given-names></name>
<name><surname>Carlin</surname><given-names>C.</given-names></name>
<name><surname>Anghelina</surname><given-names>M.</given-names></name>
<name><surname>Stevens</surname><given-names>P.</given-names></name>
<name><surname>Fernandez</surname><given-names>S.</given-names></name>
<name><surname>Jones</surname><given-names>D.</given-names></name>
<name><surname>Panchal</surname><given-names>A.R.</given-names></name>
<etal/>
</person-group><article-title>Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants</article-title><source>Cell Rep.</source><year>2023</year><volume>42</volume><fpage>112443</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2023.112443</pub-id><pub-id pub-id-type="pmid">37104089</pub-id>
</element-citation></ref><ref id="B27-viruses-17-00168"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>A.</given-names></name>
<name><surname>Wei</surname><given-names>P.</given-names></name>
<name><surname>Man</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Ji</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Huo</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>J.</given-names></name>
</person-group><article-title>Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>125</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01391-x</pub-id><pub-id pub-id-type="pmid">36922506</pub-id>
</element-citation></ref><ref id="B28-viruses-17-00168"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>N.</given-names></name>
<name><surname>Trost</surname><given-names>J.F.</given-names></name>
<name><surname>Guebre-Xabier</surname><given-names>M.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Norton</surname><given-names>J.</given-names></name>
<name><surname>Jiang</surname><given-names>D.</given-names></name>
<name><surname>Cai</surname><given-names>Z.</given-names></name>
<name><surname>Zhu</surname><given-names>M.</given-names></name>
<name><surname>Marchese</surname><given-names>A.M.</given-names></name>
<name><surname>Greene</surname><given-names>A.M.</given-names></name>
<etal/>
</person-group><article-title>XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>19176</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-46025-y</pub-id><pub-id pub-id-type="pmid">37932354</pub-id>
</element-citation></ref><ref id="B29-viruses-17-00168"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Regan</surname><given-names>J.J.</given-names></name>
<name><surname>Moulia</surname><given-names>D.L.</given-names></name>
<name><surname>Link-Gelles</surname><given-names>R.</given-names></name>
<name><surname>Godfrey</surname><given-names>M.</given-names></name>
<name><surname>Mak</surname><given-names>J.</given-names></name>
<name><surname>Najdowski</surname><given-names>M.</given-names></name>
<name><surname>Rosenblum</surname><given-names>H.G.</given-names></name>
<name><surname>Shah</surname><given-names>M.M.</given-names></name>
<name><surname>Twentyman</surname><given-names>E.</given-names></name>
<name><surname>Meyer</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Use of updated COVID-19 vaccines 2023-2024 formula for persons aged &#x02265;6 months: Recommendations of the Advisory Committee on Immunization Practices&#x02014;United States, September 2023</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2023</year><volume>72</volume><fpage>1140</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7242e1</pub-id><pub-id pub-id-type="pmid">37856366</pub-id>
</element-citation></ref><ref id="B30-viruses-17-00168"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Panagiotakopoulos</surname><given-names>L.</given-names></name>
<name><surname>Godfrey</surname><given-names>M.</given-names></name>
<name><surname>Moulia</surname><given-names>D.L.</given-names></name>
<name><surname>Link-Gelles</surname><given-names>R.</given-names></name>
<name><surname>Taylor</surname><given-names>C.A.</given-names></name>
<name><surname>Chatham-Stephens</surname><given-names>K.</given-names></name>
<name><surname>Brooks</surname><given-names>O.</given-names></name>
<name><surname>Daley</surname><given-names>M.F.</given-names></name>
<name><surname>Fleming-Dutra</surname><given-names>K.E.</given-names></name>
<name><surname>Wallace</surname><given-names>M.</given-names></name>
</person-group><article-title>Use of an additional updated 2023-2024 COVID-19 vaccine dose for adults aged &#x02265;65 years: Recommendations of the advisory committee on immunization practices&#x02014;United States, 2024</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2024</year><volume>73</volume><fpage>377</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7316a4</pub-id><pub-id pub-id-type="pmid">38662708</pub-id>
</element-citation></ref><ref id="B31-viruses-17-00168"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qu</surname><given-names>P.</given-names></name>
<name><surname>Xu</surname><given-names>K.</given-names></name>
<name><surname>Faraone</surname><given-names>J.N.</given-names></name>
<name><surname>Goodarzi</surname><given-names>N.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.M.</given-names></name>
<name><surname>Carlin</surname><given-names>C.</given-names></name>
<name><surname>Bednash</surname><given-names>J.S.</given-names></name>
<name><surname>Horowitz</surname><given-names>J.C.</given-names></name>
<name><surname>Mallampalli</surname><given-names>R.K.</given-names></name>
<name><surname>Saif</surname><given-names>L.J.</given-names></name>
<etal/>
</person-group><article-title>Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants</article-title><source>Cell</source><year>2024</year><volume>187</volume><fpage>585</fpage><lpage>595.e6</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.12.026</pub-id><pub-id pub-id-type="pmid">38194968</pub-id>
</element-citation></ref><ref id="B32-viruses-17-00168"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Jian</surname><given-names>F.</given-names></name>
<name><surname>Song</surname><given-names>W.</given-names></name>
<name><surname>Yisimayi</surname><given-names>A.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>e70</fpage><lpage>e72</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(23)00744-2</pub-id><pub-id pub-id-type="pmid">38109919</pub-id>
</element-citation></ref><ref id="B33-viruses-17-00168"><label>33.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Infectious Diseases Society of America</collab>
</person-group><article-title>COVID-19 variant update&#x02014;4 September 2024</article-title><comment>Available online: <ext-link xlink:href="https://www.idsociety.org/covid-19-real-time-learning-network/diagnostics/covid-19-variant-update/#/+/0/publishedDate_na_dt/desc/" ext-link-type="uri">https://www.idsociety.org/covid-19-real-time-learning-network/diagnostics/covid-19-variant-update/#/+/0/publishedDate_na_dt/desc/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-09">(accessed on 9 September 2024)</date-in-citation></element-citation></ref><ref id="B34-viruses-17-00168"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaku</surname><given-names>Y.</given-names></name>
<name><surname>Okumura</surname><given-names>K.</given-names></name>
<name><surname>Padilla-Blanco</surname><given-names>M.</given-names></name>
<name><surname>Kusogi</surname><given-names>Y.</given-names></name>
<name><surname>Uriu</surname><given-names>K.</given-names></name>
<name><surname>Hinay</surname><given-names>A.A.</given-names><suffix>Jr.</suffix></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Plianchaisuk</surname><given-names>A.</given-names></name>
<name><surname>Kobiyama</surname><given-names>K.</given-names></name>
<name><surname>Ishii</surname><given-names>K.J.</given-names></name>
<etal/>
</person-group><article-title>Virological characteristics of the SARS-CoV-2 JN.1 variant</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>e82</fpage><pub-id pub-id-type="doi">10.1016/S1473-3099(23)00813-7</pub-id><pub-id pub-id-type="pmid">38184005</pub-id>
</element-citation></ref><ref id="B35-viruses-17-00168"><label>35.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>US Food and Drug Administration</collab>
</person-group><article-title>Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2024</article-title><comment>Available online: <ext-link xlink:href="https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2024" ext-link-type="uri">https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2024</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-09">(accessed on 9 September 2024)</date-in-citation></element-citation></ref><ref id="B36-viruses-17-00168"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Showers</surname><given-names>W.M.</given-names></name>
<name><surname>Leach</surname><given-names>S.M.</given-names></name>
<name><surname>Kechris</surname><given-names>K.</given-names></name>
<name><surname>Strong</surname><given-names>M.</given-names></name>
</person-group><article-title>Longitudinal analysis of SARS-CoV-2 spike and RNA-dependent RNA polymerase protein sequences reveals the emergence and geographic distribution of diverse mutations</article-title><source>Infect. Genet. Evol.</source><year>2022</year><volume>97</volume><fpage>105153</fpage><pub-id pub-id-type="doi">10.1016/j.meegid.2021.105153</pub-id><pub-id pub-id-type="pmid">34801754</pub-id>
</element-citation></ref><ref id="B37-viruses-17-00168"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martin</surname><given-names>R.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Parvangada</surname><given-names>A.</given-names></name>
<name><surname>Perry</surname><given-names>J.</given-names></name>
<name><surname>Cihlar</surname><given-names>T.</given-names></name>
<name><surname>Mo</surname><given-names>H.</given-names></name>
<name><surname>Porter</surname><given-names>D.</given-names></name>
<name><surname>Svarovskaia</surname><given-names>E.</given-names></name>
</person-group><article-title>Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir</article-title><source>Antivir. Res.</source><year>2021</year><volume>188</volume><fpage>105033</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2021.105033</pub-id><pub-id pub-id-type="pmid">33549572</pub-id>
</element-citation></ref><ref id="B38-viruses-17-00168"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pitts</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Perry</surname><given-names>J.K.</given-names></name>
<name><surname>Pont</surname><given-names>V.D.</given-names></name>
<name><surname>Riola</surname><given-names>N.</given-names></name>
<name><surname>Rodriguez</surname><given-names>L.</given-names></name>
<name><surname>Lu</surname><given-names>X.</given-names></name>
<name><surname>Kurhade</surname><given-names>C.</given-names></name>
<name><surname>Xie</surname><given-names>X.</given-names></name>
<name><surname>Camus</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants</article-title><source>Antimicrob. Agents Chemother.</source><year>2022</year><volume>66</volume><fpage>e0022222</fpage><pub-id pub-id-type="doi">10.1128/aac.00222-22</pub-id><pub-id pub-id-type="pmid">35532238</pub-id>
</element-citation></ref><ref id="B39-viruses-17-00168"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Song</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Yuan</surname><given-names>Z.</given-names></name>
<name><surname>Yi</surname><given-names>Z.</given-names></name>
</person-group><article-title>A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2</article-title><source>Antivir. Res.</source><year>2021</year><volume>185</volume><fpage>104974</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104974</pub-id><pub-id pub-id-type="pmid">33217430</pub-id>
</element-citation></ref><ref id="B40-viruses-17-00168"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hedskog</surname><given-names>C.</given-names></name>
<name><surname>Rodriguez</surname><given-names>L.</given-names></name>
<name><surname>Roychoudhury</surname><given-names>P.</given-names></name>
<name><surname>Huang</surname><given-names>M.L.</given-names></name>
<name><surname>Jerome</surname><given-names>K.R.</given-names></name>
<name><surname>Hao</surname><given-names>L.</given-names></name>
<name><surname>Ireton</surname><given-names>R.C.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Perry</surname><given-names>J.K.</given-names></name>
<name><surname>Han</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Viral resistance analyses from the remdesivir phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)</article-title><source>J. Infect. Dis.</source><year>2023</year><volume>228</volume><fpage>1263</fpage><lpage>1273</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiad270</pub-id><pub-id pub-id-type="pmid">37466213</pub-id>
</element-citation></ref><ref id="B41-viruses-17-00168"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hedskog</surname><given-names>C.</given-names></name>
<name><surname>Spinner</surname><given-names>C.D.</given-names></name>
<name><surname>Protzer</surname><given-names>U.</given-names></name>
<name><surname>Hoffmann</surname><given-names>D.</given-names></name>
<name><surname>Ko</surname><given-names>C.</given-names></name>
<name><surname>Gottlieb</surname><given-names>R.L.</given-names></name>
<name><surname>Askar</surname><given-names>M.</given-names></name>
<name><surname>Roestenberg</surname><given-names>M.</given-names></name>
<name><surname>de Vries</surname><given-names>J.J.C.</given-names></name>
<name><surname>Carbo</surname><given-names>E.C.</given-names></name>
<etal/>
</person-group><article-title>No remdesivir resistance observed in the phase 3 severe and moderate COVID-19 SIMPLE trials</article-title><source>Viruses</source><year>2024</year><volume>16</volume><elocation-id>546</elocation-id><pub-id pub-id-type="doi">10.3390/v16040546</pub-id><pub-id pub-id-type="pmid">38675889</pub-id>
</element-citation></ref><ref id="B42-viruses-17-00168"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Malone</surname><given-names>B.</given-names></name>
<name><surname>Llewellyn</surname><given-names>E.</given-names></name>
<name><surname>Grasso</surname><given-names>M.</given-names></name>
<name><surname>Shelton</surname><given-names>P.M.M.</given-names></name>
<name><surname>Olinares</surname><given-names>P.D.B.</given-names></name>
<name><surname>Maruthi</surname><given-names>K.</given-names></name>
<name><surname>Eng</surname><given-names>E.T.</given-names></name>
<name><surname>Vatandaslar</surname><given-names>H.</given-names></name>
<name><surname>Chait</surname><given-names>B.T.</given-names></name>
<etal/>
</person-group><article-title>Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex</article-title><source>Cell</source><year>2020</year><volume>182</volume><fpage>1560</fpage><lpage>1573.e13</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.07.033</pub-id><pub-id pub-id-type="pmid">32783916</pub-id>
</element-citation></ref><ref id="B43-viruses-17-00168"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malone</surname><given-names>B.F.</given-names></name>
<name><surname>Perry</surname><given-names>J.K.</given-names></name>
<name><surname>Olinares</surname><given-names>P.D.B.</given-names></name>
<name><surname>Lee</surname><given-names>H.W.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Appleby</surname><given-names>T.C.</given-names></name>
<name><surname>Feng</surname><given-names>J.Y.</given-names></name>
<name><surname>Bilello</surname><given-names>J.P.</given-names></name>
<name><surname>Ng</surname><given-names>H.</given-names></name>
<name><surname>Sotiris</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Structural basis for substrate selection by the SARS-CoV-2 replicase</article-title><source>Nature</source><year>2023</year><volume>614</volume><fpage>781</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05664-3</pub-id><pub-id pub-id-type="pmid">36725929</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-17-00168-f001"><label>Figure 1</label><caption><p>Dose&#x02013;response curves of SARS-CoV-2 clinical isolates treated with RDV and ODV. A549-hACE2-TMPRSS2 cells were infected with the WA1 reference strain or Omicron variant clinical isolates at a multiplicity of infection of 0.05 and treated with 3-fold serial dilutions of (<bold>A</bold>) RDV (starting at 5 &#x000b5;M) or (<bold>B</bold>) ODV (starting at 50 &#x000b5;M). At 72 h post infection, an intracellular SARS-CoV-2 nucleoprotein antibody ELISA was used to detect viral replication and calculate percent inhibition by RDV and ODV. Each variant was tested two times with technical triplicates. The range of 24 replicates of the wildtype WA1 reference strain is shaded in gray. ELISA, enzyme-linked immunosorbent assay; ODV, obeldesivir; RDV, remdesivir.</p></caption><graphic xlink:href="viruses-17-00168-g001" position="float"/></fig><fig position="float" id="viruses-17-00168-f002"><label>Figure 2</label><caption><p>Map of Nsp12 amino acid polymorphisms observed in Omicron variants at &#x02265;1% frequency. The structure is a model of the active NTP in the SARS-CoV-2 active site based on the cryo-electron microscopy structures 6XEZ [<xref rid="B42-viruses-17-00168" ref-type="bibr">42</xref>] and 7UO4 [<xref rid="B43-viruses-17-00168" ref-type="bibr">43</xref>]. The pre-incorporated active NTP metabolite of remdesivir and obeldesivir is shown in cyan. The Nsp12 protein is shown in green, with the locations of the observed polymorphisms shown in magenta. Other replication complex components, Nsp7, Nsp8 (two subunits), and Nsp13 (two subunits), are shown in white, yellow, and orange, respectively. The template RNA strand is shown in blue and the nascent RNA strand is shown in red. NTP, nucleoside triphosphate; RNA, ribonucleic acid.</p></caption><graphic xlink:href="viruses-17-00168-g002" position="float"/></fig><table-wrap position="float" id="viruses-17-00168-t001"><object-id pub-id-type="pii">viruses-17-00168-t001_Table 1</object-id><label>Table 1</label><caption><p>Phenotyping of Omicron variants and site-directed mutants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
</th><th rowspan="2" colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Substitutions in the<break/>Replication Complex <sup>a</sup></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">RDV</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">ODV</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean EC<sub>50</sub> &#x000b1; SD<break/>(nM) <sup>b</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fold Change &#x000b1; SD <sup>c</sup> From Wildtype <sup>d</sup><break/>Reference</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean EC<sub>50</sub> &#x000b1; SD<break/>(nM) <sup>b</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fold Change &#x000b1; SD <sup>c</sup> From Wildtype <sup>d</sup><break/>Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Variant lineage<break/>(clinical isolates) <sup>e</sup></td><td colspan="6" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2 <break/>reference strain <break/>(WA1; lineage A) <sup>f</sup></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">&#x02013;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Range, 58&#x02013;165</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Range, 1240&#x02013;4125</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.00</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BA.2.86 <sup>f</sup></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nsp9 T35I<break/>Nsp12 P323L<break/>Nsp13 R392C<break/>Nsp14 I42V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.0 &#x000b1; 0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.36 &#x000b1; 0.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">438 &#x000b1; 52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.23 &#x000b1; 0.03</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BF.7 <sup>f</sup></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nsp12 P323L<break/>Nsp13 R392C<break/>Nsp14 I42V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">120 &#x000b1; 24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.25 &#x000b1; 0.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2644 &#x000b1; 230</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.24 &#x000b1; 0.04</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BQ.1 <sup>f</sup></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nsp12 P323L Y273H<break/>Nsp13 M233I R392C<break/>Nsp14 I42V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.8 &#x000b1; 2.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.53 &#x000b1; 0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1410 &#x000b1; 113</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.66 &#x000b1; 0.02</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CH.1.1 <sup>f</sup></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nsp8 N118S<break/>Nsp12 P323L G671S<break/>Nsp13 R392C<break/>Nsp14 I42V V182I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">155 &#x000b1; 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.95 &#x000b1; 0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1835 &#x000b1; 50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.62 &#x000b1; 0.16</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EG.1.2 <sup>g</sup></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nsp9 T35I<break/>Nsp12 P323L G671S<break/>Nsp13 S36P R392C<break/>Nsp14 I42V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59.9 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.87 &#x000b1; 0.23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1090 &#x000b1; 57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.86 &#x000b1; 0.03</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EG.5.1 <sup>g</sup></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nsp9 T35I<break/>Nsp12 P323L G671S<break/>Nsp13 S36P R392C<break/>Nsp14 I42V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44.4 &#x000b1; 0.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.58 &#x000b1; 0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">903 &#x000b1; 243</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.47 &#x000b1; 0.04</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EG.5.1.4 <sup>h</sup></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nsp9 T35I<break/>Nsp12 P323L G671S<break/>Nsp13 S36P R392C<break/>Nsp14 I42V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44.3 &#x000b1; 7.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.40 &#x000b1; 0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1473 &#x000b1; 379</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.41 &#x000b1; 0.01</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FL.22 <sup>i</sup></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nsp9 T35I<break/>Nsp12 P323L<break/>Nsp13 S36P R392C<break/>Nsp14 I42V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.9 &#x000b1; 10.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.15 &#x000b1; 0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2070 &#x000b1; 28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.88 &#x000b1; 0.03</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HK.3 <sup>g</sup></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nsp9 T35I<break/>Nsp12 D63N P323L G671S<break/>Nsp13 S36P R392C<break/>Nsp14 I42V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.3 &#x000b1; 1.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.04 &#x000b1; 0.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1921 &#x000b1; 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.03 &#x000b1; 0.24</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HV.1 <sup>h</sup></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nsp9 T35I<break/>Nsp12 P323L G671S<break/>Nsp13 R392C <break/>Nsp14 I42V V182I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">135 &#x000b1; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.93 &#x000b1; 0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3193 &#x000b1; 513</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.92 &#x000b1; 0.34</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">JN.1 <sup>f</sup></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nsp9 T35I<break/>Nsp12 P323L<break/>Nsp13 R392C<break/>Nsp14 I42V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.0 &#x000b1; 3.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.28 &#x000b1; 0.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">912 &#x000b1; 99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.31 &#x000b1; 0.02</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBB.1.5 <sup>f</sup></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nsp12 P323L G671S<break/>Nsp13 S36P R392C<break/>Nsp14 I42V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76.7 &#x000b1; 18.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.81 &#x000b1; 0.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2249 &#x000b1; 143</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.06 &#x000b1; 0.13</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBB.1.5.72 <sup>h</sup></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nsp12 P323L G671S<break/>Nsp13 S36P R392C<break/>Nsp14 I42V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">82.8 &#x000b1; 10.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.75 &#x000b1; 0.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2271 &#x000b1; 66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.66 &#x000b1; 0.17</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBB.1.16 <sup>i</sup></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nsp12 P323L G671S<break/>Nsp13 S36P R392C<break/>Nsp14 I42V D222Y</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.4 &#x000b1; 5.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.73 &#x000b1; 0.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1475 &#x000b1; 35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.63 &#x000b1; 0.01</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBB.2.3.2 <sup>i</sup></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nsp12 P323L G671S<break/>Nsp13 R392C<break/>Nsp14 I42V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.8 &#x000b1; 4.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.29 &#x000b1; 0.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">671 &#x000b1; 205</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.30 &#x000b1; 0.03</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBC.1.6 <sup>i</sup></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nsp12 P323L G671S G823insD<break/>Nsp13 P77L T127I I33V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.9 &#x000b1; 4.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.46 &#x000b1; 0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">638 &#x000b1; 352</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.26 &#x000b1; 0.13</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBF <sup>i</sup></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nsp8 N118S<break/>Nsp12 P323L G671S<break/>Nsp13 R392C<break/>Nsp14 I42V V182I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">102 &#x000b1; 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.22 &#x000b1; 0.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2345 &#x000b1; 7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.99 &#x000b1; 0.05</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Variant lineage<break/>(replicon system) <sup>j</sup></td><td colspan="6" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2 reference (SH01; lineage B)</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">&#x02013;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Range, 10.9&#x02013;11.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Range, 375&#x02013;526</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.00</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">JN.1.7<break/>JN.1.18<break/>KP.2<break/>KP.3<break/>LB.1</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Nsp9 T35I<break/>Nsp12 P323L<break/>Nsp13 S36P R392C<break/>Nsp14 I42V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.6 &#x000b1; 1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.14 &#x000b1; 0.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">465 &#x000b1; 45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.05 &#x000b1; 0.15</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Omicron lineage</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Polymorphism</bold>
<break/>
<bold>frequency,</bold>
<break/>
<bold>% (n)</bold>
</td><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nsp12 polymorphism (replicon system)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2 reference (SH01; lineage B)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Range, 4.4&#x02013;13.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Range, 390&#x02013;965</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.00</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T26I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BA.2.86</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3 (10) <sup>k</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.39 &#x000b1; 0.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.23 &#x000b1; 0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">856 &#x000b1; 41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.17 &#x000b1; 0.002</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">D40G</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BQ.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2 (624) <sup>k</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.3 &#x000b1; 3.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.16 &#x000b1; 0.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">690 &#x000b1; 90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.20 &#x000b1; 0.31</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">D63N</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EG.5.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.6 (699) <sup>k</sup></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">15.1 &#x000b1; 0.1</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.25 &#x000b1; 0.14</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">791&#x000b1; 42</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.23 &#x000b1; 0.06</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HK.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.8 (30,557) <sup>k</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T85I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EG.5.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.1(305) <sup>k</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.88 &#x000b1; 0.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.87 &#x000b1; 0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">839 &#x000b1; 3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.17 &#x000b1; 0.05</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G108D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BJ.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.8 (3) <sup>k</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.85 &#x000b1; 0.36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.81 &#x000b1; 0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not tested</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">D155G</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BA.2.3.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.9 (25) <sup>l</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.94 &#x000b1; 0.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.39 &#x000b1; 0.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">212 &#x000b1; 32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.47 &#x000b1; 0.10</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I171V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EG.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0 (14) <sup>m</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.01 &#x000b1; 2.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.19 &#x000b1; 0.44</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">633 &#x000b1; 87</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.11 &#x000b1; 0.10</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y175H</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CH.1.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2 (237) <sup>k</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.60 &#x000b1; 0.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.10 &#x000b1; 0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">690 &#x000b1; 31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.21 &#x000b1; 0.004</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I223M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBB.1.9.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.9 (329) <sup>k</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.2 &#x000b1; 1.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.52 &#x000b1; 0.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">767 &#x000b1; 35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.33 &#x000b1; 0.23</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T225I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DV.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.5 (39) <sup>m</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.00 &#x000b1; 0.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.53 &#x000b1; 0.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1022 &#x000b1; 51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.39 &#x000b1; 0.002</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L247F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BF.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.1 (1661) <sup>k</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.95 &#x000b1; 0.94</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.52 &#x000b1; 0.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">681 &#x000b1; 50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.80 &#x000b1; 0.19</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T248I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BF.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.0 (1292) <sup>n</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.33 &#x000b1; 0.58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.93 &#x000b1; 0.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">387 &#x000b1; 47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.85 &#x000b1; 0.16</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V257F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBB.1.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.1 (4819) <sup>n</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.84 &#x000b1; 0.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.19 &#x000b1; 0.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">215 &#x000b1; 9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.47 &#x000b1; 0.05</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">D258N</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBB.1.9.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0 (93) <sup>k</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.0 &#x000b1; 5.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.01 &#x000b1; 0.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">817 &#x000b1; 11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.27 &#x000b1; 0.01</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y273H</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BQ.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.0 (52,625) <sup>k</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.74 &#x000b1; 0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.00 &#x000b1; 0.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">228 &#x000b1; 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.50 &#x000b1; 0.03</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y289H</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBB.2.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.4 (125) <sup>k</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.8 &#x000b1; 4.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.32 &#x000b1; 0.47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">987 &#x000b1; 121</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.54 &#x000b1; 0.20</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">D303N</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BA.2.86</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.9 (130) <sup>o</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.9 &#x000b1; 0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.40 &#x000b1; 0.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">563 &#x000b1; 10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.97 &#x000b1; 0.10</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P323L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Across <break/>Omicron subvariants</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.8 (16,265,492) <sup>k</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.21 &#x000b1; 0.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.94 &#x000b1; 0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">333 &#x000b1; 32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.78 &#x000b1; 0.19</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T394M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BA.2.86</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.8 (15) <sup>o</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.42 &#x000b1; 0.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.03 &#x000b1; 0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">574 &#x000b1; 18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.06 &#x000b1; 0.12</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P461S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBB.1.9.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.7 (209) <sup>k</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.0 &#x000b1; 5.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.60 &#x000b1; 0.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">641 &#x000b1; 206</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.08 &#x000b1; 0.21</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V476A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EG.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0 (8) <sup>p</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.68 &#x000b1; 0.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.55 &#x000b1; 0.002</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">329 &#x000b1; 49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.51 &#x000b1; 0.08</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N507I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.8 (176) <sup>k</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.29 &#x000b1; 0.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.85 &#x000b1; 0.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">369 &#x000b1; 16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.67 &#x000b1; 0.01</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A529V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BF.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3 (693) <sup>k</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Did not<break/>replicate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Did not replicate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M666I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBB.1.9.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.4 (249) <sup>q</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.83 &#x000b1; 2.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.80 &#x000b1; 0.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">603 &#x000b1; 193</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.94 &#x000b1; 0.30</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">G671S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBB.1.5 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.7 (177,617) <sup>k</sup></td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">15.5 &#x000b1; 1.1</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.60 &#x000b1; 0.10</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1322 &#x000b1; 17</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.76 &#x000b1; 0.09</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CH.1.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.5 (18,857) <sup>k</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.0 (9552) <sup>k</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F694Y</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.4 (239) <sup>k</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Did not<break/>replicate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Did not replicate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T803I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBB.2.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.5 (75) <sup>r</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.31 &#x000b1; 0.002</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.56 &#x000b1; 0.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">370 &#x000b1; 37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.64 &#x000b1; 0.15</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G823insD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBC.1.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89.7 (1155) <sup>k</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.30 &#x000b1; 1.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.75 &#x000b1; 0.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">740 &#x000b1; 17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.03 &#x000b1; 0.07</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V848I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBB.1.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5 (900)<sup>m</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.4 &#x000b1; 2.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.11&#x000b1; 0.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">847 &#x000b1; 70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.32 &#x000b1; 0.10</td></tr></tbody></table><table-wrap-foot><fn><p>BEI, Biodefense and Emerging Infectious Research; EC<sub>50</sub>, half-maximal effective concentration; GISAID, Global Initiative on Sharing Avian Influenza Data; NA, not applicable; ODV, obeldesivir; RDV, remdesivir; SD, standard deviation. <sup>a</sup> The characteristic substitutions for a lineage are defined as nonsynonymous substitutions or deletions that occur in &#x02265;75% of sequences within that lineage. <sup>b</sup> EC<sub>50</sub> &#x000b1; SD values represent the mean of &#x02265;2 independent experiments. <sup>c</sup> Fold change &#x000b1; SD represents the mean of &#x02265;2 independent experiments. Fold change was calculated for each experiment, from which the mean fold change was calculated. <sup>d</sup> For clinical isolates, the wildtype SARS-CoV-2 reference strain was the WA1 strain (lineage A). For the replicon system, the wildtype SARS-CoV-2 reference strain was the SH01 replicon (lineage B). <sup>e</sup> The clinical isolates used in this study were: BF.7 (hCoV-19/USA/MD-HP38288/2022; NR-58974; deposited to BEI by Dr. Andrew Pekosz), BQ.1 (hCoV-19/USA/MD-HP38960/2022; NR-58975; deposited to BEI by Dr. Andrew Pekosz), XBB.1.5 (hCoV-19/USA/MD-HP40900/2022; NR-59104; deposited to BEI by Dr. Andrew Pekosz), CH.1.1 (hCoV-19/USA/MD-HP41275/2022; NR-59204; deposited to BEI by Dr. Andrew Pekosz), XBF (hCoV-19/Japan/TY41-831/2022; TY41-831), XBB.1.6 (hCoV-19/Japan/TY41-984/2023; TY41-984), FL.22 (hCoV-19/Japan/TY41-951/2023; TY41-951), JN.1 (hCoV-19/USA/New York/PV96109/2023; NR-59693), XBB.2.3.2 (hCoV-19/Japan/TY42-006/2023), EG.5.1 (hCoV-19/USA/MD-HP47946), EG.1.2 (hCoV-19/USA/MD-HP46933-PIDKWGVVMR/2023), XBC.1.6 (hCoV-19/Japan/TY42-004/2023), HK.3 (hCoV-19/USA/MD-HP49292-PIDWKNSGGH/2023), BA.2.86 (hCoV-19/USA/MI-UM-10052670540/2023; NR-59638; deposited to BEI by the Centers for Disease Control and Prevention), HV.1 (hCoV-19/USA/CA-GS137943/2024), XBB.1.5.72 (hCoV-19/USA/CA-GS136867/2024), and EG.5.1.4 (hCoV-19/USA/CA-GS138000/2024). <sup>f</sup> Sourced from BEI Repository. <sup>g</sup> Sourced from Johns Hopkins University. <sup>h</sup> Sourced from Gilead Sciences, Inc. <sup>i</sup> Sourced from National Institute of Infectious Diseases, Japan. <sup>j</sup> EC<sub>50</sub> values from variants tested using the replicon system cannot be directly compared with variants tested using clinical isolates due to differences in assay reagents, conditions, and detection technology. Fold change values, which are independent of the assay used, offer a more accurate basis for comparison. <sup>k</sup> Frequency of the observed polymorphism in the GISAID database as of 7 August 2024. <sup>l</sup> Was observed at &#x02265;1% frequency (2.9%, D155G) in the GISAID database on 28 November 2022, but has since decreased below 1%. <sup>m</sup> Was observed at &#x02265;1% frequency (1.0%, I171V; 10.5%, T225I; 2.5%, V848I) in the GISAID database on 10 August 2023 but has since decreased below 1%. <sup>n</sup> Was observed at &#x02265;1% frequency (2.0%, T248I; 3.1% V257F) in the GISAID database on 6 April 2023 but has since decreased below 1%. <sup>o</sup> Was observed at &#x02265;1% frequency (15.9%, D303N; 1.8%, T394M) in the GISAID database on 4 March 2024 but has since decreased below 1%. <sup>p</sup> Was observed at &#x02265;1% frequency (1.0%, V476A) in the GISAID database on 3 October 2023 but has since decreased below 1%. <sup>q</sup> Was observed at &#x02265;1% frequency (1.4%, M666I) in the GISAID database on 1 June 2023 but has since decreased below 1%. <sup>r</sup> Was observed at &#x02265;1% frequency (1.5%, T803I) in the GIAID database on 5 September 2023 but has since decreased below 1%.</p></fn></table-wrap-foot></table-wrap></floats-group></article>